Day: November 17, 2017

  1. Home
  2. Archives: November 2017

Orphazyme, joint portfolio company of ALS Investment Fund and LSP, raises approximately €80 million in oversubscribed IPO

Orphazyme, joint portfolio company of ALS Investment Fund and LSP, raises approximately €80 million in oversubscribed IPO

Recent Posts

  • Prilenia enrolls first ALS patient in their Phase II / III study
  • Emulate unveils brain chip to enhance neuroinflammatory disease research and drug discovery which will support drug development for ALS
  • Prilenia shows positive effect on functional capacity in Huntigton’s Disease
  • Orphazyme submits marketing authorization in Europe for the treatment of Niemann Pick Disease
  • Emulate signs a strategic partnership with the FDA

ROBERT BROWN

Scientific Advisory Board